Table of Contents
A Technology & Pipeline Assessment and Corporate Benchmarking Analysis
The report “Recombinant Coagulation Factors 2013 – The Race to Market and for Market Shares: Technology & Pipeline Assessment and Corporate Benchmarking Analysis” of June 2013 describes a market forecast based on growth of historical sales of recombinant coagulation factors. The report evaluates reasons for failures of novel recombinant coagulation factors and provides detailed profiles of active recombinant coagulation factors in clinical development. Preclinical projects are valued on the basis of the underlying technologies. Emerging alternative therapeutic approaches are described and assessed. The detailed target pipeline assessments put emphasis on the competitive situation regarding stage of development, inhibitor profile, half-life, administration frequency, clinical success and especially time to approval/market. The pipelines of the clinically active companies are described and their competitive position assessed in light of the key success factors. Sources of information are LMP’s proprietary database, scientific literature (abstracts, papers), corporate information (press releases, presentations, reports, SEC filings). All information is referenced.
Combined product sales of the three classes olf recombinant coagulation factors used in hemophilia were US$ 7.172 mln in 2012. The pipeline of new recombinant coagulation factors is maturing and the first molecules are under regulatory review by the FDA and the EMA and many have entered pivotal clinical studies. There are 46 different molecules and R&D approaches for novel recombinant coagulation factors for hemophilia A and B in the pipeline of which 24 are in clinical development of under regulatory review. Given this tight competition, time-to-market will be an important success. This report will explain the potential development and approval timelines of each of the advanced molecules.
What will you find in this report?
• Historical sales data of the recombinant coagulation factors VIII, IX, VIIa and II;
• Historical growth rates and a 5-year sales forecast of each class of recombinant factors;
• Reasons for failure and profiles of failed recombinant coagulation factors;
• Detailed profiles of clinical stage recombinant coagulation factors;
• Technologies used for creation of novel recombinant coagulation factors;
• Preclinical stage recombinant coagulation factors;
• New approaches: alternative procoagulants / adjuncts and gene therapy;
• Pipeline analysis and assessment for each recombinant coagulation factor class;
• Comparative data on clinical inhibitor formation and discussion of its relevance;
• Comparison of half-life prolongation and its impact on administration frequency;
• Comparison of the time to approval for each clinical stage recombinant coagulation factor;
• Company pipeline and competitive position of each major player in the field
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
About Factor VIII Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia ...
DelveInsight’s, “Factor VIII Inhibitors-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Factor VIII Inhibitors. The ...
The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...